Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 3/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | OGG1 | O15527 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1000463 | 1.00 | CES2 (0.44) | CES2CES1HTTCA1CA2 | |
| SCHEMBL936431 | 1.00 | CES2 (0.44) | CES2CES1HTTCA1CA2 | |
| SCHEMBL11814265 | 0.87 | ALDH1A1 (0.33) | LMNA | |
| SCHEMBL27128218 | 0.82 | CES2 (0.46) | CES2CES1HTTCA1CA2 | |
| SCHEMBL17223079 | 0.82 | CES2 (0.46) | CES2CES1HTTCA1CA2 | |
| SCHEMBL17223080 | 0.82 | CES2 (0.46) | CES2CES1HTTCA1CA2 | |
| SCHEMBL24484065 | 0.78 | CES2 (0.42) | CES2CES1HTTCA1CA2 | |
| SCHEMBL28418670 | 0.78 | CES2 (0.42) | CES2CES1CA1CA2CYP2A6 | |
| SCHEMBL10045039 | 0.77 | MEN1 (0.50) | HTTCA1CA2ESR1ESR2 | |
| SCHEMBL4039683 | 0.77 | TSHR (0.50) | CES2CES1CA1CA2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569336-B2 | Compounds for the treatment of inflammatory disorders | TONG LING (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569336-B2 | Compounds for the treatment of inflammatory disorders | TONG LING (US) | 2013-10-29 | — | — | US | disclosed |
| US-8541572-B2 | Compounds for the treatment of inflammatory disorders | MERCK SHARP & DOHME CORP. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541572-B2 | Compounds for the treatment of inflammatory disorders | MERCK SHARP & DOHME CORP. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8450355-B2 | Compounds for the treatment of inflammatory diseases | MERCK SHARP & DOHME CORP. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450355-B2 | Compounds for the treatment of inflammatory diseases | MERCK SHARP & DOHME CORP. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TONG LING (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TONG LING (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120010181-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | MERCK SHARP & DOHME CORP. | 2012-01-12 | — | — | US | disclosed |
| US-20120010181-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | MERCK SHARP & DOHME CORP. | 2012-01-12 | — | — | US | disclosed |
| US-20110288077-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES | SCHERING CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110288077-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES | SCHERING CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
| WO-2011009484-A1 | ARYLPYRAZOLES AND ARYLISOXAZOLES AND THEIR USE AS PKD MODULATORS | NOVARTIS AG (CH) | 2011-01-27 | — | — | WO | disclosed |
| WO-2010054279-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010054278-A2 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288077-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES | TNF, ADAMTS13, MMP11 | CES2 814/4885CES1 160/4885HTT 860/4885 |
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, ADAMTS1, ADAMTS7 | CES2 671/4885CES1 167/4885HTT 955/4885 |
| US-20120010181-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, ADAMTS1, ADAMTS7 | CES2 532/4885CES1 105/4885HTT 1153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.